Prostate cancer (PCa), the second most common cancer affecting men worldwide, shows a broad spectrum of biological and clinical behaviour representing the epiphenomenon of an extreme heterogeneity. Androgen deprivation therapy is the mainstay of treatment for advanced forms but after few years the majority of patients progress to castration-resistant prostate cancer (CRPC), a lethal form that poses considerable therapeutic challenges.
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
FERRARI, NICOLETTA;CAPAIA, MATTEO GINO LINO;Brizzolara, Antonella;Astigiano, Simonetta;Amaro, Adriana Agnese;Boccardo, Francesco;
2017-01-01
Abstract
Prostate cancer (PCa), the second most common cancer affecting men worldwide, shows a broad spectrum of biological and clinical behaviour representing the epiphenomenon of an extreme heterogeneity. Androgen deprivation therapy is the mainstay of treatment for advanced forms but after few years the majority of patients progress to castration-resistant prostate cancer (CRPC), a lethal form that poses considerable therapeutic challenges.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
12964_2017_Article_206.pdf
accesso aperto
Tipologia:
Documento in versione editoriale
Dimensione
4.32 MB
Formato
Adobe PDF
|
4.32 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
